COMP <GO>
EW vs JNJ // DIVIDEND YIELD & FCF PAYOUT SAFETY
Edwards Lifesciences Corporation (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: EW 3
— JNJ 8
■ METRIC PARITY
LAST: $92.01 (-2.57%) • MKT CAP: $54.44B
dividend-safety
0.00%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EW VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EW | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 78.00% | 67.90% | +10.10 | EW | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 12.50% | 25.50% | -13.00 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 35.1x | 18.5x | +16.60 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 2.45% | 2.97% | -0.52 | JNJ | /fcf-yield <GO> |
| Operating Margin | 20.80% | 34.70% | -13.90 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 17.70% | 28.50% | -10.80 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 11.50% | 6.00% | +5.50 | EW | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.36 | 5.59 | +6.77 | EW | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.20% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 59.9 | 60.4 | -0.48 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.08 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 47.2x | 23.0x | +24.20 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $54.44B | $662.49B | -$608.06B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EW REV | JNJ REV | EW GROSS % | JNJ GROSS % | EW FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.07B | $94.19B | 78.0% | 67.9% | $1.33B | $19.70B |
| FY 2024 | $5.44B | $88.82B | 79.5% | 69.1% | $289.9M | $19.84B |
| FY 2023 | $5.01B | $85.16B | 44.0% | 44.0% | $670.4M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EW // BETA 1.08
JNJ // BETA 1.08